Education Realty Trust, Inc. (EDR) Analysts See $0.55 EPS; 4 Analysts Bullish OncoMed Pharmaceuticals, Inc. (OMED)

April 24, 2018 - By Louis Casey

Education Realty Trust, Inc. (NYSE:EDR) Logo

Analysts expect Education Realty Trust, Inc. (NYSE:EDR) to report $0.55 EPS on April, 30 before the open.They anticipate $0.05 EPS change or 8.33% from last quarter’s $0.6 EPS. EDR’s profit would be $41.83M giving it 14.45 P/E if the $0.55 EPS is correct. After having $0.59 EPS previously, Education Realty Trust, Inc.’s analysts see -6.78% EPS growth. The stock decreased 0.81% or $0.26 during the last trading session, reaching $31.79. About 528,730 shares traded or 0.06% up from the average. Education Realty Trust, Inc. (NYSE:EDR) has declined 20.25% since April 24, 2017 and is downtrending. It has underperformed by 31.80% the S&P500.

Among 10 analysts covering OncoMed Pharmaceuticals (NASDAQ:OMED), 4 have Buy rating, 0 Sell and 6 Hold. Therefore 40% are positive. OncoMed Pharmaceuticals had 21 analyst reports since September 9, 2015 according to SRatingsIntel. Jefferies initiated OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) on Wednesday, September 9 with “Buy” rating. As per Friday, March 9, the company rating was maintained by H.C. Wainwright. The firm has “Buy” rating by Mizuho given on Tuesday, January 26. Jefferies maintained it with “Buy” rating and $16 target in Wednesday, August 10 report. As per Tuesday, April 12, the company rating was initiated by BMO Capital Markets. The stock of OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has “Market Perform” rating given on Tuesday, April 11 by BMO Capital Markets. The rating was initiated by H.C. Wainwright with “Buy” on Thursday, September 22. The company was initiated on Friday, December 4 by Wells Fargo. JMP Securities maintained OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) rating on Wednesday, March 9. JMP Securities has “Market Outperform” rating and $18 target. The firm earned “Buy” rating on Monday, April 18 by Cantor Fitzgerald. See OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) latest ratings:

20/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $3.0 Maintain
09/03/2018 Broker: H.C. Wainwright Rating: Hold New Target: $3.0 Maintain
08/03/2018 Broker: SunTrust Rating: Hold New Target: $3.0 Maintain

Investors sentiment decreased to 1.36 in Q4 2017. Its down 0.36, from 1.72 in 2017Q3. It is negative, as 27 investors sold Education Realty Trust, Inc. shares while 61 reduced holdings. 31 funds opened positions while 89 raised stakes. 78.96 million shares or 2.56% less from 81.03 million shares in 2017Q3 were reported. State Of Tennessee Treasury Department has 0% invested in Education Realty Trust, Inc. (NYSE:EDR). Laurion Cap Management Ltd Partnership owns 9,700 shares for 0% of their portfolio. Nuveen Asset Mgmt Ltd Limited Liability Company stated it has 288,264 shares or 0.06% of all its holdings. Principal Financial Grp holds 331,759 shares. Moreover, Blackrock has 0.02% invested in Education Realty Trust, Inc. (NYSE:EDR). 39,341 were accumulated by State Board Of Administration Of Florida Retirement Sys. Smithfield Trust holds 0% or 70 shares in its portfolio. 54,537 are owned by Arizona State Retirement Systems. Lasalle Mngmt Ltd reported 17,942 shares or 0.01% of all its holdings. Citadel Advisors Ltd Llc has 0% invested in Education Realty Trust, Inc. (NYSE:EDR). Rhumbline Advisers accumulated 0.01% or 165,749 shares. Deprince Race & Zollo reported 0.74% in Education Realty Trust, Inc. (NYSE:EDR). Huntington Bank & Trust holds 0% or 620 shares in its portfolio. Jane Street Group Incorporated Limited owns 15,311 shares or 0% of their US portfolio. Employees Retirement Association Of Colorado has 0% invested in Education Realty Trust, Inc. (NYSE:EDR) for 1,183 shares.

Among 16 analysts covering Education Realty Trust (NYSE:EDR), 5 have Buy rating, 2 Sell and 9 Hold. Therefore 31% are positive. Education Realty Trust had 51 analyst reports since July 23, 2015 according to SRatingsIntel. Canaccord Genuity downgraded Education Realty Trust, Inc. (NYSE:EDR) on Tuesday, April 11 to “Hold” rating. The stock of Education Realty Trust, Inc. (NYSE:EDR) has “Buy” rating given on Wednesday, June 7 by RBC Capital Markets. On Thursday, November 17 the stock rating was upgraded by Hilliard Lyons to “Neutral”. The firm has “Hold” rating by Sandler O’Neill given on Monday, February 26. The rating was upgraded by Goldman Sachs to “Buy” on Thursday, August 10. The stock of Education Realty Trust, Inc. (NYSE:EDR) earned “Outperform” rating by FBR Capital on Tuesday, August 2. The company was maintained on Monday, July 31 by RBC Capital Markets. Robert W. Baird maintained it with “Buy” rating and $45.0 target in Monday, September 25 report. The stock has “Buy” rating by Canaccord Genuity on Thursday, February 2. As per Thursday, February 22, the company rating was maintained by Robert W. Baird.

EdR is one of America's largest owners, developers and managers of collegiate housing. The company has market cap of $2.42 billion. EdR is a self-administered and self-managed real estate investment trust that owns or manages 87 communities with more than 46,200 beds serving 54 universities in 26 states. It has a 52.98 P/E ratio.

The stock decreased 7.59% or $0.24 during the last trading session, reaching $2.92. About 134,712 shares traded. OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) has declined 65.75% since April 24, 2017 and is downtrending. It has underperformed by 77.30% the S&P500.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $111.72 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

Investors sentiment increased to 1.62 in Q4 2017. Its up 0.91, from 0.71 in 2017Q3. It improved, as 3 investors sold OncoMed Pharmaceuticals, Inc. shares while 18 reduced holdings. 15 funds opened positions while 19 raised stakes. 19.21 million shares or 47.57% more from 13.02 million shares in 2017Q3 were reported. Burt Wealth invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Vanguard Group reported 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Northern Corporation reported 59,017 shares. Meeder Asset holds 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) for 1,096 shares. New York-based Fny Managed Accounts Lc has invested 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Cannell Peter B Inc invested 0.04% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Paloma Prns Mgmt Com invested in 32,858 shares. Art Advisors Limited Liability has 0% invested in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Millennium Management Limited Liability Co invested in 0% or 543,335 shares. Hodges Cap Mgmt stated it has 0% in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Zacks Invest reported 21,597 shares or 0% of all its holdings. Alyeska Invest Grp Lp owns 521,883 shares for 0.02% of their portfolio. Renaissance Technologies Ltd Liability Co has invested 0% of its portfolio in OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED). Primecap Mgmt Company Ca owns 5.57 million shares. Virtu Fincl Limited holds 0.01% or 41,395 shares.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>